At the well-controlled HbA1c of the participants, previous literature shows current diabetes treatments have similar HbA1c decreases, so the HbA1c mean difference of long half-life PDE5 inhibitors may ...

Learn about the use of PDE5 inhibitors for lower urinary tract symptoms caused by premature ejaculation and BPH.

Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allows the body to react swiftly to stress or starvation.

Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allow the body to react swiftly to stress or starvation. Critical to this "fight ...

The number of patients utilizing PDE-5 inhibitors to maintain a healthy sex life continues to expand as telehealth and direct-to-consumer channels expand around the world.

Cyclic nucleotide phosphodiesterase-8 (PDE8) is a family of cAMP-specific enzymes and plays important roles in many biological processes, including T-cell activation, testosterone production, ...

This condition negatively affects his sexual performance and the performance of his partner. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to treat ED. Arginase II plays an important ...

Objective Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in patients with type 2 diabetes, with ...

Phosphodiesterase 5 (PDE5) inhibitors, owing to their mechanism of action, have been gaining recognition as a potential case of drug repurposing and combination therapy for diabetes treatment. We ...

Understanding protein kinases' role in diseases like cancer is crucial for drug development. Researchers from Okayama University have introduced a novel inhibitor, targeting Adaptor Protein 2 ...

Men with primary organic vs psychogenic ED have a significant 81% increased risk of nonadherence to phosphodiesterase type 5 inhibitor therapy. The likelihood of adherence to oral drug therapies ...